Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02706951 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 648
- Enrollment target
NCT02706951 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 648 participants.
The verdict
NCT02706951, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 648 participants
- Enrollment target
Study Summary
The study objective of Period 1 of this study is to compare the safety and efficacy (signs and symptoms) of upadacitinib 30 mg once daily (QD) alone and upadacitinib 15 mg QD alone versus continuing MTX alone adults with moderately to severely active rheumatoid arthritis (RA) with an inadequate response to MTX. The study objective of Period 2 is to evaluate the long term safety, tolerability, and efficacy of upadacitinib 30 mg QD and 15 mg QD in adults with RA who had completed Period 1.
Interventions
- DRUG Upadacitinib
- DRUG Methotrexate
- DRUG Placebo Upadacitinib
- DRUG Placebo Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 648 participants |
| Start Date | 2016-03-23 |
| Est. Completion | 2022-08-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02706951
The ClinicalTrials.gov registry entry for NCT02706951 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 648 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Upadacitinib is the first listed.
NCT02706951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02706951 about?
NCT02706951 is a clinical study titled "A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)". The study objective of Period 1 of this study is to compare the safety and efficacy (signs and symptoms) of upadacitinib 30 mg once daily (QD) alone and upadacitinib 15 mg QD alone versus continuing MTX alone adults with moderately to severely active rheumatoid arthritis (RA) with an inadequate resp...
What is the current status of trial NCT02706951?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 648 participants. The study started on 2016-03-23. Estimated completion is 2022-08-10.
What interventions are being tested in trial NCT02706951?
The interventions under investigation include: Upadacitinib (DRUG), Methotrexate (DRUG), Placebo Upadacitinib (DRUG), Placebo Methotrexate (DRUG).
Who is sponsoring clinical trial NCT02706951?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.